Menu

Blog

Apr 14, 2020

NanoViricides, Inc. Progress on COVID-19 Drug Encouraging

Posted by in categories: biotech/medical, nanotechnology

The company’s update on its development of COVID-19 drug candidate is promising.

Vancouver, British Columbia—(Newsfile Corp. — March 31, 2020) — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) is a nano-biopharmaceutical Company at the development stage, with proprietary and patented drug development work focused on viral diseases. The Company’s research involves the use of a unique nanomedicine technology called nanoviricides — agents designed to “fool” a virus into attaching to an antiviral nanomachine, in the same way that the virus normally attaches to the receptors on a cell surface, but for the purpose of its neutralization and destruction. NanoViricides was highlighted by SmallCapsDaily for providing an update on its progress to develop a drug that can treat COVID-19, the coronaviral pneumonia disease which is caused by the SARS-CoV-2 virus, aka, 2019-nCoV, also known as the Wuhan coronavirus.

Leave a reply